Study Helps Validates Sarepta Therapeutic's (SRPT) Technology

April 9, 2013 5:34 PM EDT Send to a Friend
Deutsche Bank today maintained a Buy rating on Sarepta Therapeutic (NASDAQ: SRPT) with a price target of $45.00. Data on ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login